Yoon, Dok Hyun
Cao, Junning
Chen, Tsai-Yun
Izutsu, Koji
Kim, Seok Jin
Kwong, Yok Lam
Lin, Tong Yu
Thye, Lim Soon
Xu, Bing
Yang, Deok Hwan
Kim, Won Seog
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 4 December 2019
Accepted: 3 March 2020
First Online: 17 March 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Won Seog Kim reports research funding from Johnson & Johnson, Kyowa-Kirin, Pfizer, Roche, Donga, and Celltrion. Koji Izutsu reports the following disclosures related to the treatment of MCL: grants and personal fees from Celgene, grants and personal fees from Eisai, grants and personal fees from Janssen, grants and personal fees from Mundipharma, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Abbvie, grants and personal fees from Zenyaku, grants from Symbio, and personal fees from Kyowa Hakko Kirin outside the submitted work. Dok-Hyun Yoon reports research funding from Johnson & Johnson and consulting fees from Johnson & Johnson, Celgene, and Celltrion. Junning Cao, Tsai-Yun Chen, Seok Jin Kim, Yok Lam Kwong, Tony Yu Lin, Lim Soon Thye, Bing Xu, and Duk Hwan Yong report no competing interests.